Xerostomia Therapeutics Market Trends

Growth Drivers

• Advancements in drug innovations: This is one of the primary drivers in the xerostomia therapeutics market, as the worldwide population is disproportionately affected by dry mouth. In this regard, Eisai Co. Ltd. in 2024 launched EVOXAC (cevimeline) in chewable form, which remarkably improved compliance by 42%. Besides, it is reported that phase II stem cell therapy trials for salivary gland regeneration demonstrated a 52% symptom reduction, fostering a positive outlook for this sector.
• Improvements in healthcare quality: This is yet another driver that positively impacts the xerostomia therapeutics market across all nations. As stated by the AHRQ report in 2022, an early intervention with saliva stimulants reduced hospitalizations by 22.4%, saving approximately USD 1.2 billion in the U.S. healthcare expenditure over two years. Further, in Germany, the Disease Management Program for Sjögren’s syndrome improved xerostomia treatment adherence by 30.5%, thereby lowering complications.

Historical Patient Growth and Its Impact on Xerostomia Therapeutics Market Expansion

The xerostomia therapeutics market is fundamentally undergoing modification owing to the aspect of steady rise in the patient pool over the last decade. Besides, there is a surge in aging demographics, autoimmune diseases, and growing incorporation of xerostomia-inducing medications such as antihypertensives and antidepressants. This expansion in terms of the patient pool has directly benefited manufacturers and suppliers in aspect of revenue, particularly in established nations, as there is higher treatment accessibility. Simultaneously in emerging markets are witnessing unmet medical needs, encouraging the key players to invest in this sector.

Historical Patient Growth (2010–2020) in Key Markets

Manufacturer Strategies Driving Xerostomia Therapeutics Market Expansion

Manufacturers involved in the xerostomia therapeutics market leverage product innovation in the form of chewable formulations and biologics, collaborations with oncology units, and expansion into emerging markets with a collective goal to strengthen their market positions. Esai Co. Ltd captured a 13.6% additional market share in 2023 with the launch of chewable tablets addressing compliance issues in elderly patients. Meanwhile, in the U.S., GSK’s Biotene announced a partnership with dental clinics to enhance OTC products with radiotherapy post care, thereby accelerating the revenue by USD 181 million. Hence, these tactics have reshaped the competitive landscape, pushing smaller players to focus on niche segments such as pediatric xerostomia.

Revenue Growth Opportunities for Xerostomia Manufacturers (2023–2025)

Challenge

• Barriers in regulatory procedures: The major challenge causing hindrance to the xerostomia therapeutics market is the delays in terms of stringent regulatory frameworks. In this regard, PMDA data in 2022 unveiled that in Japan, the saliva stimulant approvals were delayed by 6 months owing to the strict safety reviews. Further, in 2023, the U.S. FDA’s backlog for medical devices such as electrostimulation tools pushed the launch to 2025, making it challenging for xerostomia manufacturers to leverage the therapeutics.